Generic low-molecular-weight heparins: some practical considerations.
about
Characterization of anticoagulant heparinoids by immunoprofiling.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics CommitteesComparative glycomics using a tetraplex stable-isotope coded tag.Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells.Low-molecular-weight heparins and angiogenesis.Management of venous thromboembolism in patients with cancer: role of dalteparin.The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro.Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism.Determination of the molecular weight of low-molecular-weight heparins by using high-pressure size exclusion chromatography on line with a triple detector array and conventional methods.Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
P2860
Q33376879-C142B8C3-CBD4-4D12-826A-FE4AC4DE4AF6Q33685447-35CB7351-5227-450D-BF53-3CAA0A7B665FQ33765274-2D147897-95E2-4977-96C1-390EE101FF4AQ33789401-F47FA25B-A9BF-41F3-8DEC-34490AC17F23Q33790809-0895DABF-5B57-4F97-B093-87CC7E75A6E5Q34635335-BFA53E04-F03B-4819-9AAA-AA9A2D3D9FE5Q36216588-A196EEEF-AA44-4A7B-B079-7A7314D16E7EQ36414904-BA5708E4-1D64-4DD9-8348-ABE310C2E6F5Q36812767-60EAE093-526E-4769-9C62-46440CA6D1A4Q39252361-4550074F-4917-413F-A07E-708F922146E8Q39963957-7FB8976C-915B-455F-8DEA-43E349A27FD1Q41212817-162DA840-A144-4DC3-AE57-66CEF21E5FBCQ43042778-56DFD4EA-B5F9-422C-943A-670C9563A04DQ46753849-4F372902-B3D9-4815-95D5-936A50A7DB69Q47188749-2C9B456B-4D5C-4009-9A4E-D485F1F64B9DQ47290768-8C505639-D845-44F9-BFEC-D9B47CB395F6Q47316913-F71C4040-E0C5-4273-A51D-C880D922525C
P2860
Generic low-molecular-weight heparins: some practical considerations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Generic low-molecular-weight heparins: some practical considerations.
@ast
Generic low-molecular-weight heparins: some practical considerations.
@en
type
label
Generic low-molecular-weight heparins: some practical considerations.
@ast
Generic low-molecular-weight heparins: some practical considerations.
@en
prefLabel
Generic low-molecular-weight heparins: some practical considerations.
@ast
Generic low-molecular-weight heparins: some practical considerations.
@en
P2093
P356
P1476
Generic low-molecular-weight heparins: some practical considerations.
@en
P2093
Debra A Hoppensteadt
Jawed Fareed
Jeanine Walenga
Raisesh Wahi
Rodger L Bick
Walter P Jeske
Wendy L Leong
P304
P356
10.1055/S-2004-861513
P577
2004-12-01T00:00:00Z